Executive Profiles

Executive Roundtable

Leadership

Press Releases

Corporate Communications

Healthcare Access

Patient Education

Telehealth

Direct-to-Consumer

Funding

Partnerships

Emerging Biopharma

Finance

Industry Trends

IR Licensing and Partnerships

Patient Access

Pricing

Strategy

Market Access

Clinical Data

Patient Advocacy

Pharmacovigilance

Medical Affairs

R&D/Clinical Trials

Supply Chain

Sustainability

Technology

Operations

DE&I

Patient Engagement

Global

Legal

Regulatory

Campaigns

DTC Marketing

Medical Education

Sales Effectiveness

Sales & Marketing

News

Academy

Multimedia

Editorial Podcasts

Editorial Videos

Peer Exchange

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Partner Perspectives

Resources

Content Engagement Hubs

E-Books

Events

Webcasts

Whitepapers

Subscribe

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

About

Advertise

Contact Us

Editorial Board

Editorial Submission Guidelines

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Executive - Leadership, Strategy & Market Access

LinkedIN

Instagram

Facebook

Threads

Bluesky

Spotlight

Latest Executive Roundtables

Asembia 2025 

Topic

Sales and Marketing

1rem

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, explores:

How AI can potentially revolutionize patient engagement and adherence

Utilizing patient-level data and predictive modeling

How AI can identify individual needs and preferences

The importance of ethical considerations and data privacy when leveraging AI in healthcare

Podcasts

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Powering learnings of the dark genome to tackle disease at its source. 

An RNA-Guided Path

Pushing for access wins in quickly evolving market and digital health landscapes.


Acceleration and Ambition

Ex-Wall Street trader is helping reshape how patients receive biologics.


Driving Disruption in Delivery

Pioneer of cell-reset technology steers science-to-startup transformation. 


Determined Problem-Solver

The AeroRx Therapeutics CEO discusses new treatments and how the industry at large is reacting to them.

Creating Momentum for COPD Treatments: Q&A with Dr. Ahmet Tutuncu

Where AI Delivers Value in Healthcare and Where the Hype Falls Short

, Rob Abbott, CEO of ISPOR, discussed how health economics and outcomes research (HEOR) is transforming the way health systems and governments around the world address rising drug prices. Abbott highlighted the growing importance of real-world evidence, patient-centered approaches, and artificial intelligence in shaping value-based healthcare decisions. He also emphasized the critical role of cross-sector collaboration among regulators, payers, academia, and industry in advancing evidence-based policies and improving patient access to innovative therapies.

Pharmaceutical Executive: How is AI currently being used in HEOR to improve patient outcomes or cost-efficiency, and where do you believe the hype may be outpacing reality?

I’ll start with the second part of your question. There’s a tremendous amount of excitement—and optimism—around the possibilities of artificial intelligence. At the same time, there’s also concern about ceding too much control to “the algorithm.” The way I see it, AI needs to be framed properly. It’s an extraordinary tool, but it’s still just a tool. We need guardrails and oversight to ensure human intelligence remains at the center.

In practice, AI is already proving useful. For example, it can perform systematic literature reviews and synthesize research in a fraction of the time it would take a human team—days, weeks, or even months. That efficiency is a major benefit.

What excites me even more is AI’s ability to structure complex datasets, accelerate analysis, and support personalized medicine. Imagine a physician tailoring a treatment protocol based on AI’s ability to rapidly synthesize vast amounts of patient data. That’s where the potential to improve outcomes really shines.

That said, the promise of AI should always be viewed through the lens of oversight. It can help us become more efficient—and hopefully more effective—in patient care. But humans must still provide the fact-checking to ensure AI-generated insights truly serve patients’ best interests.

 Health economics and outcomes research (HEOR) is increasingly shaping how health systems and governments address rising drug prices. HEOR integrates clinical trial results, real-world data, patient experiences, and economic analysis to evaluate medical interventions. By assessing a treatment’s cost-effectiveness and real-world value, HEOR informs value-based pricing and decision-making, going beyond traditional clinical trial data to determine how drugs perform in everyday patient care.

A key trend highlighted in ISPOR’s 2024–2025 Top 10 Trends report is the growing importance of real-world evidence. Unlike clinical trials, real-world evidence captures patient outcomes, side effects, and overall cost-effectiveness after drugs enter the market, making it critical for both policy and clinical decisions. Another transformative trend is the accelerated adoption of artificial intelligence (AI) and digital health tools. AI is being used to synthesize literature, analyze complex data sets, and tailor treatment protocols efficiently. However, experts caution that while AI offers significant potential, human oversight remains essential to ensure patient-centered care.

From a global perspective, US healthcare excels in certain areas, such as cancer screening, vaccination rates, and advanced medical technology, but faces challenges including high per-capita costs, lack of universal coverage, and suboptimal outcomes in chronic disease and life expectancy. These issues highlight the universal challenge of managing rising costs amid increasing complexity.

Collaboration across government, academia, and industry is critical to advance evidence-based health policy and patient access. Organizations like ISPOR, with its global membership spanning regulators, payers, patient organizations, and academics, are fostering these partnerships. Initiatives, such as pilot projects aligning regulators and health technology assessment agencies in Europe, illustrate how coordinated efforts can improve patient access to innovative therapies while navigating the complexities of cost, efficacy, and healthcare delivery.

Overall, HEOR, real-world evidence, AI, and multi-stakeholder collaboration are central to shaping efficient, patient-centered, and cost-conscious healthcare systems worldwide.

Videos

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

Video Series

Future Partnership Plans for GT-02287 and the Magellan Platform in Parkinson’s Research

, Gene Mack, CEO, Gain Therapeutics, shared promising updates on the company’s lead candidate, GT-02287, a novel therapy in development for Parkinson’s disease. Enrollment for the Phase Ib open-label trial wrapped three months ahead of schedule, driven by growing clinician confidence in the drug’s safety and therapeutic potential. Originally designed for patients with a GBA1 gene mutation—a known disruptor of the GCase enzyme—GT-02287 has shown early signs of benefit across a broader Parkinson’s population. With biomarker data expected in Q4 2025, Gain is preparing for a pivotal Phase II trial in early 2026 while weighing financing options and potential strategic partnerships, all hinging on forthcoming efficacy and biomarker insights.

Pharmaceutical Executive: Are there plans for partnerships or licensing agreements tied to GT-02287 or the Magellan platform?

We’ll need to make several important decisions in the fourth quarter, once we receive the first relevant data set from Parkinson’s disease patients. Depending on the efficacy results and biomarker impact of GT-02287, we’ve been actively engaging with potential partners—including large pharma, mid-cap pharma, large biotech, and some mid-cap biotech companies. There’s a healthy level of interest among companies focused on neurodegenerative diseases.

That said, neurodegenerative disease remains a very challenging area. Unlike oncology or autoimmune diseases, conditions like Alzheimer’s and Parkinson’s have seen less progress, so there’s considerable risk aversion given the high failure rate in this space. We’ve been discussing this program with potential partners for several years, and now we’re approaching a critical stage.

At this point, the industry may choose to collaborate with us to advance the molecule, or we may decide to finance further development ourselves through capital markets. Both options are on the table, and we’ll see what the Phase 1b results indicate. After that, we’ll engage with investors and partners to determine the next steps.

Our Phase II study is expected to cost around $50 to $60 million. We could either fund this ourselves, partner the asset, or pursue a combination of both.

Enrollment for the Phase Ib trial of GT-02287, a novel therapeutic candidate for Parkinson’s disease, was completed three months ahead of schedule. While the trial targeted a small cohort, momentum increased as clinicians grew more comfortable with the drug’s safety profile and potential. Initially cautious due to the investigational nature of the therapy, sites became more confident in recommending the study, reflecting growing optimism about GT-02287’s promise.

The ongoing Phase Ib trial is an open-label pilot involving 15 to 20 patients with Parkinson’s disease, including those with idiopathic PD and those with a GBA1 gene mutation. This gene mutation disrupts the production of glucocerebrosidase (GCase), a key enzyme that GT-02287 is designed to restore. Although the drug was initially developed for GBA1-mutated patients, early findings suggest it may benefit a broader PD population.

The Phase Ib readout, expected in Q4 2025, will include biomarker data from cerebrospinal fluid to assess differential efficacy between patient subtypes.

Looking ahead, a larger, double-blind Phase II trial is planned for early 2026, enrolling 100–200 patients to validate efficacy signals in a blinded setting and mitigate bias seen in open-label designs.

GT-02287 was developed using the company’s Magellan AI platform, which identifies novel binding pockets on target proteins and screens both known and hypothetical molecules. Magellan extends drug discovery into previously unexplored chemical space by predicting interactions that can be synthesized and tested.

Partnership discussions are ongoing with large pharma, biotech, and mid-cap firms. Final decisions around financing or partnering will depend on Phase Ib results. The company is prepared to either self-fund the $50–60M Phase II trial or advance through a strategic collaboration, depending on the biomarker and efficacy data in Parkinson’s patients.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease trial data.

Where Has AI Already Been Successfully Implemented?

Gen Li, president and founder of Phesi, spoke with 

 about issues pharma companies are having during Phase III trials and how new technologies can solve these issues.

Pharmaceutical Executive: What's causing so many Phase three trials to head for avoidable failure?


 The challenges can be put into two different categories. The first is: how good are we designing trial protocols? The problems that we’re seeing can be caused by a mismatch in the design and the patient population being targeted. In those cases, the trial protocol must be amended. The consequence of that is that this causes a delay and prolongs to trial time, which brings increased financial costs.

The other category is investigating the right sites and recruiting the right patients. Oftentimes, we don’t do the best ion getting the sites to recruit the patients.

These two things conjugate with each other. When you have poor design, that in and of itself can cause poor performance with enrollment, which compounds with the issues the site may already have with enrollment. The main problem is the mismatch between the experience and the knowledge of the investigator and the patients being targeted by the protocol itself. These are the issues that cause problems in Phase III.

Another issue that’s overlooked is the competition. This can come in many different levels: site, country, and even disease. Using dermatitis as an example, it’s an area that suddenly saw a lot of innovation. Everyone wanted to be the first to reach approval, hence the competition became fierce, which further impacted poor enrollment performance and prolonged the cycle times.

PE: How Can Real World Data and AI Help Solve Issues with Clinical Trials?


 AI has many different ways of helping the industry. From our perspective, we have a large patient database that we can use to construct digital patient profiles. These can be made in alignment with a particular product design and the patient population being targeted. By constructing a digital patient profile, we can then find the issues associated with the design. Oftentimes, it’s found some misalignment between what a particular clinical trial is targeting in terms of patient population and what the actual patient population may actually look like.

By solving that misalignment, this leads to better trial design. We can potentially perfect the design by looking at the outcome measures.

PE: Where has AI been successfully implemented already?


 We’re current working with three of the top 10 pharmaceutical companies to create better clinical trial designs, better patient recruitment, and improve site performance. We’re also working with a number of medium to small size companies as well.

The exciting part part of AI application in clinical development is the use of the digital patient profile, which can lead to the creation of a digital twin. These can be used to either partially or totally replace control arms. We’re not there yet, though.

We’re working with our clients to create a path forward. We’ve realized that we need a lot of stakeholders in different categories to move us in the right direction. We’re working with experts from Harvard and Oxford to build a solid medical and data foundation. We’re exploring ways of working with FDA and other regulatory agencies.

It takes a lot of players to be in the same place and looking at the technology to get us to the place where we can use the digital tools to either partially or totally replace control arms. We’re not there yet, but it’s only a matter of time.

PE: Do you have a timeline for those results?


 It could be next year, it could be two or three years. But there is no doubt, in my view, that we will get there.

Gen Li discusses the current state of technological advancement in clinical trials.

How Can Real World Data and AI Help Solve Issues with Clinical Trials?

New technology has the potential to improve trial design and patient recruitment.

What the Emrelis Approval Means for Pharma and Biotech ADC Strategies

, Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discussed how AbbVie’s newly approved antibody-drug conjugate (ADC), Emrelis, differentiates itself in a rapidly evolving oncology landscape. With rising competition in the ADC field—particularly in solid tumors—Anand highlighted Emrelis’ unique target, mechanism of action, and strategic positioning as key factors that set it apart. She also provided insight into what the approval signals about the FDA’s current regulatory posture, the potential impact on investor interest, and what a successful Phase III trial could mean for AbbVie’s long-term growth in precision oncology.

Pharmaceutical Executive: How could this approval influence investor and R&D interest in the ADC field, especially among large pharmas versus biotechs?

 The approval of Emrelis has accelerated both investor and R&D interest in the ADC space. While interest was already building, this milestone validates the potential of biomarker-driven ADCs in solid tumors. For large pharma, it signals an opportunity to diversify their pipelines with precision oncology assets that can compete with existing small molecule inhibitors and immunotherapies. It may also lead to more partnerships, acquisitions, or in-house ADC development programs—particularly those targeting underexplored antigens such as c-MET or other biomarkers linked to solid tumors.

From a biotech perspective, Emrelis' success shows that a focus on differentiated targets and innovative ADC design can translate into regulatory success. This could drive increased venture funding and more collaboration opportunities. Additionally, the approval reinforces the viability of ADCs that use established payloads like MMAE when combined with precision-targeting strategies.

Overall, the Emrelis approval is likely to spur a wave of strategic investments and competitive R&D efforts, as both pharma and biotech companies aim to replicate—or even improve upon—this success in the ADC field.

 Emrelis stands out in the crowded antibody-drug conjugate (ADC) space by targeting a highly specific biomarker—C-MET overexpression in non-small cell lung cancer (NSCLC)—rather than pursuing broader tumor indications. Unlike ADCs such as those targeting HER2 or TROP2, which are used in breast or gastric cancers, Emrelis is designed for a niche patient subgroup with high C-MET protein levels but without MET gene mutations, a population with limited treatment options. This precision-targeting approach, combined with the use of the MMAE payload via a cleavable linker (which disrupts microtubules rather than causing DNA damage like some other ADCs), sets Emrelis apart both clinically and mechanistically.

The FDA’s accelerated approval of Emrelis signals a growing willingness to support biomarker-driven ADCs in solid tumors, particularly when addressing unmet needs. It reflects confidence in ADC safety and efficacy profiles and aligns with broader trends favoring precision medicine.

Emrelis is especially well-positioned to serve NSCLC patients representing roughly 25% of EGFR wild-type cases who overexpress C-MET but lack actionable mutations. While NSCLC remains the primary focus, success here could pave the way for expansion into other C-MET–driven solid tumors.

From an industry perspective, Emrelis’ approval is likely to fuel both investor enthusiasm and R&D momentum. For large pharmaceutical companies, it offers a blueprint to diversify oncology pipelines beyond traditional small molecules or immunotherapies. For biotechs, it validates the potential of novel ADC designs targeting underexplored antigens.

If Phase III trials meet their endpoints, Emrelis could become a new standard of care in C-MET high NSCLC and mark a strategic shift for AbbVie, establishing its credibility in solid tumor oncology and reinforcing its in-house ADC capabilities amidst rising competition from companies like Daiichi Sankyo and ImmunoGen.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic paths for pharma and biotech in the evolving precision oncology landscape.

Digital Health and Biosimilars Shape the Future of Pharmacy

 sat down with Blake Powers, CEO of Medigi, to discuss the company’s role in bridging innovation and patient access in the life sciences space. Powers shared his insights on the evolving landscape of commercialization, the growing importance of digital health and automation, and how in-person connection at events such as Asembia remains critical in an increasingly virtual world. As the industry moves toward greater integration of technology and patient-centered solutions, Powers emphasized how Medigi is helping to close the gap between groundbreaking therapies and the patients who rely on them.

Pharmaceutical Executive: Are there any panels that you plan on attending that you believe will resonate with medigi’s mission or approach?

I’m excited about Blue Fin’s panel on biosimilars. Cell and gene therapy is also a hot topic right now. Many of our hospital pharmacy partners are increasingly asking how we can modernize the digital intake process for cell and gene therapies, as well as biosimilars. What role do these therapies play in today’s landscape? That’s definitely a key area I’m looking forward to. I’m also interested in the AI and automation panels—especially those focused on cutting-edge technologies. The big question is: will these innovations truly make their way into hospital pharmacy operations?

PE: How do you see the Asembia Trade Show evolving to reflect the increasing role of digital health and tech-enabled services?

I think what’s great about Asembia is that it brings together not only biopharmaceutical companies, but also the vendors who support them—across tech, trade, channel, and distribution. This is where it all converges. I see the show continuing to evolve with an increasing emphasis on technology that supports go-to-market strategies, ultimately helping patients receive the treatments they need. It also ensures healthcare providers have reliable, high-quality access points. That’s what we’re focused on at Medigi, and I believe many other tech vendors are here for the same reason. Every year, the show gets more innovative.

 For many in the life sciences industry, Asembia is seen as the "Super Bowl for Pharma," bringing together the biggest players in the field. This year, the primary goal for attendees such as those from Medigi is to foster in-person connections, moving beyond email and Zoom to build stronger, face-to-face relationships with industry partners.

Medigi’s mission is focused on bridging the gap between cutting-edge therapeutic technologies and the patients who need them. While innovation in therapies is impressive, commercialization often creates barriers between manufacturers, healthcare providers, and patients. Medigi works to complement these technologies with solutions that improve accessibility and procurement, ensuring that advancements reach patients efficiently.

Several panels at this year’s assembly align closely with Medigi’s focus. The company is particularly interested in sessions on biosimilars and cell and gene therapies—hot topics as hospital pharmacies seek to modernize their digital intake systems. In addition, panels on AI and automation are generating excitement, especially as the industry examines how emerging technologies can transform hospital pharmacy operations.

Looking more broadly, the assembly is evolving to reflect the growing role of digital health and tech-enabled services. The convergence of biotech, distribution, and technology vendors is creating a dynamic environment where innovation is driving better commercialization strategies and, ultimately, better patient access.

As the industry looks ahead to 2025—dubbed by some as the "year of the robot"—there is growing interest in how automation will impact healthcare staffing and operations. Medigi is particularly intrigued by the potential of automation to take over repetitive tasks, allowing healthcare providers to focus more on patient care. Asembia offers a front-row seat to these discussions, highlighting the technologies poised to reshape the future of healthcare.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Latest Conference Coverage

Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy

Why AI Could Be the Key to Solving Access Challenges in Healthcare

, Chip Parkinson, the new CEO of Gift Health, shared his perspective on stepping into the role and the evolving challenges and opportunities across the healthcare landscape. Drawing on a diverse background that spans manufacturers, payers, and employer consulting, Parkinson discussed how his new position places him in closer contact with patients and prescribers than ever before. He also reflected on the state of specialty pharmacy, the potential of AI to improve access and affordability, and the importance of seeking diverse viewpoints in a rapidly shifting industry.

Pharmaceutical Executive: Patient access and affordability continue to be huge focuses—did you see any new solutions or partnerships at Asembia that excite you in that area?

 Absolutely. This is a rapidly evolving space, especially with the emergence of AI and large language models. For the first time, we have the ability to analyze vast datasets—pharmacy and medical claims, refill data, first fills—and gain a true understanding of what patients are experiencing.

Take migraine, for example. It typically takes patients six years to get properly diagnosed and treated, even though it’s the leading cause of workplace disability. Once they finally reach the right therapy, they often face utilization management hurdles like step therapy or fail-first policies. These barriers exist largely because we’ve lacked the ability to integrate and interpret the data to assess the trade-offs.

When migraine medications cost just pennies or dollars per capsule, we need to rethink whether these access barriers are justified. With AI-driven data integration, we can start answering those hard questions—and ultimately, improve access for patients.

 As of today, Chip Parkinson has stepped into role of CEO at Gift Health. Reflecting on the transition, Parkinson notes that this position brings him closer to patients than at any previous point in his career. With a background spanning manufacturers, payers, and employer consulting, he now sees firsthand the daily barriers patients and prescribers face—citing the company’s volume of 4,000 daily calls and 400 chats as a window into the patient experience.

Looking ahead, Parkinson sees several evolving roles for specialty pharmacies. He highlights the opportunity to better connect prescribers, pharmacies, and patients in real time—not just through improved logistics but with greater transparency into the patient’s journey. He also points to closer collaboration between payers and pharmacies as a potential area of growth, particularly where technology allows specialty pharmacies to integrate more directly into the care team. Parkinson emphasizes that artificial intelligence could be key in analyzing complex patient data sets—such as pharmacy claims and utilization management policies—to uncover patterns and inefficiencies that currently limit access.

When asked about prescription access and affordability, Parkinson suggests that AI may help better identify systemic barriers, using migraine treatment as an example where data gaps contribute to delays in care. He also discusses the growing demand for weight-loss medications, projecting major increases in utilization. Gift Health, he says, is looking into targeted interventions in underserved regions and through employer partnerships to address access challenges more effectively.

For other healthcare leaders attending industry events, Parkinson encourages building relationships outside familiar networks. He stresses the value of engaging with those who may hold different perspectives, particularly in a rapidly changing environment where policy, drug availability, and access continue to shift.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare

Using AI and RWD to Drive Creative Decision-Making

Pharmaceutical Executive: How do agencies use RWD to drive creative decision making?

A lot of RWD consists of quantitative information. Our database of claims has about 60 million claims in it. If you talk about those as individual data elements, you can get into the trillions. That’s impressive, but it’s meaningless unless someone understands what it is.

Where AI and brand translation comes in is the ability of AI to translate across disciplines. Administrative overhead increases on the amount of resources it takes to run any sort of organization. You must manage huge amounts of information coming in that must be interpreted differently across elements of the business.

A writer that I like compared the invention of AI to the invention of the filing cabinet, which doesn’t sound super exciting. The filing cabinet is not magical, but it enables making the same information standardized and accessible across an entire enterprise. That’s where I think an agency’s ability to translate comes in, and certainly AI will be an empowering factor to this.

I have an example from inside the lab. One of my peers took our full documentation database, everything that we use to educate clients on how to use the reports on our platform and our APIs, and he put a LLM on top of it. He essentially created a search and summarization feature for any question you could think of about how the platform works. That was just a beta test, so we’re not rolling something like that out anytime soon, but it is an example of an agency’s ability to turn analyst reports into a coherent strategy and a set of tactics that will form the creative development and media deployments.

Ted Sweetser discusses turning information into usable datasets and pulling insights from them.

Using RWD to Create Personalized Engagement

Pharmaceutical Executive: How can agencies harness real-world data (RWD) to drive smarter, more personalized engagement?


 When we think about RWD, we think about claims data and healthcare observations that have been de-identified and rendered HIPPA compliant, but still allow you to get a really fine-tuned understanding about what patient challenges are, what drives decision-making, and what obstacles they may face in obtaining care.

I gravitate towards being able to go past persona-driven strategies where market research is involved much earlier in the pre-commercial or early-launch phases and things are boiled down to broad set of archetypes. We’re able to actually describe those markets in far more detail. That means that agencies should be able to shape messaging that reflects the needs and cares of the given constituency.

We think about this in healthcare in the research side of the business. This includes getting communities to have access to care. There’s a pretty well-established link in getting somebody a healthcare provider that looks like them and is able to reflect their sensitivities and concerns. A notable and unfortunate example of that is the historical record of African Americans reporting pain symptoms and not necessarily being believed by HCPs.

Being able to match the needs of the population with the brands that you’re promoting is an area where RWD can be incredibly essential.

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Technology

Latest News